ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China · Delayed Price · Currency is CNY 27.65
-0.55 (-1.95%)
Jul 29, 2026, 4:00 PM EDT
ChengDa Pharmaceuticals Revenue
ChengDa Pharmaceuticals had revenue of 128.24M CNY in the quarter ending March 31, 2026, with 68.06% growth. This brings the company's revenue in the last twelve months to 458.30M, up 48.54% year-over-year. In the year 2025, ChengDa Pharmaceuticals had annual revenue of 406.37M with 21.99% growth.
Revenue (ttm)
458.30M
Revenue Growth
+48.54%
P/S Ratio
9.14
Revenue / Employee
695.45K
Employees
659
Market Cap
4.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 406.37M | 73.24M | 21.99% |
| Dec 31, 2024 | 333.13M | -81.17M | -19.59% |
| Dec 31, 2023 | 414.30M | 2.84M | 0.69% |
| Jan 1, 2023 | 411.46M | -4.26M | -1.03% |
| Jan 1, 2022 | 415.73M | 42.69M | 11.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 25.24B |
| Jianmin Pharmaceutical Group | 3.35B |
| Jiangsu Lianhuan Pharmaceutical | 2.89B |
| Yabao Pharmaceutical Group | 2.20B |
| Fuan Pharmaceutical (Group) | 1.68B |
| Tianjin Lisheng Pharmaceutical | 1.35B |
| Bide Pharmatech | 1.35B |
| Teyi Pharmaceutical Group Co.,Ltd | 839.27M |